FR23C1041I2 - Alpha-galactosidase stabilise et ses utilisations - Google Patents

Alpha-galactosidase stabilise et ses utilisations

Info

Publication number
FR23C1041I2
FR23C1041I2 FR23C1041C FR23C1041C FR23C1041I2 FR 23C1041 I2 FR23C1041 I2 FR 23C1041I2 FR 23C1041 C FR23C1041 C FR 23C1041C FR 23C1041 C FR23C1041 C FR 23C1041C FR 23C1041 I2 FR23C1041 I2 FR 23C1041I2
Authority
FR
France
Prior art keywords
galactosidase
stabilized alpha
stabilized
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1041C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protalix Ltd
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/fr
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of FR23C1041I1 publication Critical patent/FR23C1041I1/fr
Application granted granted Critical
Publication of FR23C1041I2 publication Critical patent/FR23C1041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
FR23C1041C 2010-03-02 2023-11-02 Alpha-galactosidase stabilise et ses utilisations Active FR23C1041I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (fr) 2009-11-17 2010-11-17 Alpha galactosidase alcaline pour le traitement de la maladie de fabry
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20
EP11712340.6A EP2542675B1 (fr) 2010-03-02 2011-03-02 Alpha-galactosidase stabilisée et ses applications

Publications (2)

Publication Number Publication Date
FR23C1041I1 FR23C1041I1 (fr) 2023-12-29
FR23C1041I2 true FR23C1041I2 (fr) 2024-08-02

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1041C Active FR23C1041I2 (fr) 2010-03-02 2023-11-02 Alpha-galactosidase stabilise et ses utilisations

Country Status (25)

Country Link
EP (3) EP2542675B1 (fr)
JP (2) JP5758920B2 (fr)
KR (1) KR101928403B1 (fr)
CN (1) CN102933707B (fr)
AU (1) AU2011222452B2 (fr)
BR (2) BR112012022029B1 (fr)
CA (1) CA2791461C (fr)
DK (1) DK2865751T3 (fr)
ES (2) ES2708843T3 (fr)
FI (1) FIC20230032I1 (fr)
FR (1) FR23C1041I2 (fr)
HK (1) HK1180720A1 (fr)
HR (1) HRP20200428T1 (fr)
HU (2) HUE030959T2 (fr)
IL (2) IL221741A (fr)
IN (1) IN2012MN02262A (fr)
NL (1) NL301249I2 (fr)
NO (1) NO2023041I1 (fr)
NZ (2) NZ623294A (fr)
PL (1) PL2865751T3 (fr)
RU (1) RU2604795C2 (fr)
SG (2) SG10201502609QA (fr)
SI (1) SI2865751T1 (fr)
WO (1) WO2011107990A1 (fr)
ZA (1) ZA201206725B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
HUE030959T2 (en) * 2010-03-02 2017-06-28 Protalix Ltd Stabilized alpha-galactosidase and its uses
EP2665814B1 (fr) * 2011-01-20 2017-05-17 Protalix Ltd. Construction d'acide nucléique pour l'expression d'une alpha-galactosidase chez des plantes et des cellules végétales
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
WO2016105889A1 (fr) * 2014-12-22 2016-06-30 Codexis, Inc. Variants d'alpha-galactosidase humaine
WO2016116966A1 (fr) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes
JP6936150B2 (ja) 2015-03-17 2021-09-15 エレヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングｅｌｅｖａ ＧｍｂＨ グリコシル化リソソームタンパク質、その製造方法および使用
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2019008076A (es) * 2017-01-05 2019-08-29 Protalix Ltd Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
EP3636751B1 (fr) * 2017-06-07 2024-01-10 Amano Enzyme Inc. Poudre de lactase en vrac et préparation de lactase
AU2019403323A1 (en) 2018-12-20 2021-07-01 Codexis, Inc. Human alpha-galactosidase variants
EP4240423A1 (fr) 2020-11-03 2023-09-13 Protalix Ltd. Uricase modifiée et ses utilisations
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (fr) 1991-10-03 1993-04-04 Guy Ampleman Polymere de glycidylazide
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
AU8772498A (en) * 1997-09-05 1999-03-29 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
CZ303751B6 (cs) * 1998-08-06 2013-04-24 Mountain View Pharmaceuticals, Inc. Farmaceutický prostredek urikasy, lécivo, pouzití a zpusob prípravy
EP1172372B1 (fr) 1999-04-02 2005-08-31 Ajinomoto Co., Inc. Procede de production de sous-unite de peptide issue d'une proteine de polymere
EP1523548B1 (fr) 2002-05-15 2009-12-30 Agricultural Research Organization Sequences de polynucleotides codant pour des alpha-galactosidases alcalines et methodes d'utilisation
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
PL1877099T3 (pl) * 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
WO2007058381A1 (fr) * 2005-11-18 2007-05-24 Tokyo Metropolitan Organization For Medical Research Nouvelle enzyme extrêmement fonctionnelle ayant une spécificité de substrat modifiée
US20100144008A1 (en) 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (fr) 2007-02-09 2008-08-13 Scil proteins GmbH Conjugué multimère
AU2008290217B2 (en) * 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
HUE030959T2 (en) * 2010-03-02 2017-06-28 Protalix Ltd Stabilized alpha-galactosidase and its uses

Also Published As

Publication number Publication date
KR101928403B1 (ko) 2018-12-14
WO2011107990A1 (fr) 2011-09-09
EP2865751A1 (fr) 2015-04-29
JP2014237694A (ja) 2014-12-18
ZA201206725B (en) 2013-06-26
AU2011222452B2 (en) 2015-09-03
AU2011222452A1 (en) 2012-09-27
CN102933707A (zh) 2013-02-13
EP3088514B1 (fr) 2018-11-28
NL301249I2 (nl) 2023-12-14
JP5758920B2 (ja) 2015-08-05
KR20130056216A (ko) 2013-05-29
HUE030959T2 (en) 2017-06-28
HK1180720A1 (en) 2013-10-25
HRP20200428T1 (hr) 2020-06-12
SI2865751T1 (sl) 2017-01-31
JP5871999B2 (ja) 2016-03-01
EP2542675A1 (fr) 2013-01-09
NZ623294A (en) 2015-10-30
NL301249I1 (fr) 2023-11-08
EP2865751B1 (fr) 2016-09-14
SG10201502609QA (en) 2015-05-28
BR112012022029A2 (pt) 2021-05-18
JP2013520986A (ja) 2013-06-10
SG183558A1 (en) 2012-10-30
ES2606532T3 (es) 2017-03-24
BR122014021216A2 (pt) 2021-06-01
EP2542675B1 (fr) 2014-12-17
RU2012141651A (ru) 2014-04-10
ES2708843T3 (es) 2019-04-11
FR23C1041I1 (fr) 2023-12-29
HUS2300038I1 (hu) 2023-11-28
IL253249A (en) 2019-08-29
DK2865751T3 (en) 2017-01-09
NO2023041I1 (no) 2023-11-01
IL221741A (en) 2017-07-31
IL253249B (en) 2020-08-31
CA2791461C (fr) 2019-10-22
RU2604795C2 (ru) 2016-12-10
EP3088514A1 (fr) 2016-11-02
FIC20230032I1 (fi) 2023-11-02
BR112012022029B1 (pt) 2022-10-11
CA2791461A1 (fr) 2011-09-09
CN102933707B (zh) 2015-09-30
PL2865751T3 (pl) 2017-03-31
NZ602317A (en) 2014-04-30
IN2012MN02262A (fr) 2015-06-12

Similar Documents

Publication Publication Date Title
FR23C1041I2 (fr) Alpha-galactosidase stabilise et ses utilisations
HK1205586A1 (en) Menu level advocate and reward system
BR112012027159A2 (pt) estrutura e método
BR112013009069A2 (pt) instrumentação unida ao paciente e métodos
BR112013012078A2 (pt) inibidores de nampt e rock
DK2553090T3 (da) Termostabile phytasevarianter
DK2613884T3 (da) Findelingsindretning
BR112013009579A2 (pt) método e comprimido
DK2353927T3 (da) Forankrings-system og indretninger
BR112013014936A2 (pt) decomposição e mesclagem de expressões regulares
BR112012019626A2 (pt) estrutura de plantio e métodos.
FR2964937B1 (fr) Triporteur et direction de triporteur
IT1401910B1 (it) Composizione fotoattiva stabilizzata e suo utilizzo
BR112013012004A2 (pt) luminária e módulo
FR2963943B1 (fr) Sas de confinement
FR2968201B1 (fr) Complexe saspase-flg2, agents modulateurs et utilisations
FR2943345B1 (fr) Analogues de la temporine-sha et leurs utilisations
FR2990696B1 (fr) Souche productrice de turanose et utilisations
BR112012033340A2 (pt) conjunto de trituração
IT1400866B1 (it) Cassa di alloggiamento e custodia per oggetti allungati
IT1398456B1 (it) Apparato di combustione a pellet e/o a biomasse.
FR2992145B1 (fr) Rhizotron et utilisations de celui-ci.
FR2955741B1 (fr) Composition herbicide et utilisations
BR112013014731A2 (pt) tamavidina modificada
TWM388803U (en) Lamp-tube stabilizer module and its lamp-tube module